Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How long do you continue ursodiol for VOD prophylaxis after gemtuzumab ozogamicin for good-risk AML
Related Questions
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
Does treating CLL reduce the risk of non-melanoma skin cancers?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
How do you manage ocular hemorrhages while on acalabrutinib for CLL?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
